ORGO vs. AMRN, VRCA, FBLG, PGEN, ANRO, TERN, SKYE, NBTX, VTYX, and ACIU
Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Amarin (AMRN), Verrica Pharmaceuticals (VRCA), FibroBiologics (FBLG), Precigen (PGEN), Alto Neuroscience (ANRO), Terns Pharmaceuticals (TERN), Skye Bioscience (SKYE), Nanobiotix (NBTX), Ventyx Biosciences (VTYX), and AC Immune (ACIU). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Organogenesis currently has a consensus target price of $4.83, suggesting a potential upside of 81.02%. Amarin has a consensus target price of $1.08, suggesting a potential upside of 28.94%. Given Organogenesis' stronger consensus rating and higher possible upside, research analysts clearly believe Organogenesis is more favorable than Amarin.
In the previous week, Amarin had 6 more articles in the media than Organogenesis. MarketBeat recorded 9 mentions for Amarin and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.91 beat Amarin's score of 0.83 indicating that Organogenesis is being referred to more favorably in the media.
Organogenesis has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Amarin received 746 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 66.21% of users gave Organogenesis an outperform vote.
Organogenesis has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Organogenesis has a net margin of 1.34% compared to Amarin's net margin of -18.96%. Organogenesis' return on equity of 2.11% beat Amarin's return on equity.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Comparatively, 2.0% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Organogenesis beats Amarin on 13 of the 18 factors compared between the two stocks.
Get Organogenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organogenesis Competitors List
Related Companies and Tools
